PRODUCT
Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows
Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression
FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra
GSK Advances Co-Administration of RSV and Shingles Vaccines with Positive Phase III Data
GSK, RSV vaccine, Shingles vaccine, Arexvy, Shingrix, co-administration, Phase III data, adult immunization
Applied Therapeutics Stock Surges After FDA Cancels Advisory Meeting for Govorestat
Applied Therapeutics, FDA, Govorestat, Advisory Meeting, Classic Galactosemia, Stock Surge
IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck
IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer
WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer
Zealand Pharma’s GLP-1/GLP-2 Receptor Dual Agonist Shows Promising Weight Loss in Phase 1b Trial
Zealand Pharma, GLP-1/GLP-2 receptor dual agonist, dapiglutide, obesity, weight loss, Phase 1b trial